Unity Biotechnology Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $38.26 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Unity Biotechnology Inc had its IPO on 2018-05-03 under the ticker symbol UBX.
The company operates in the Healthcare sector and Biotechnology industry. Unity Biotechnology Inc has a staff strength of 22 employees.
Shares of Unity Biotechnology Inc opened at $2.48 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.47 - $2.55, and closed at $2.51.
This is a +1.21% increase from the previous day's closing price.
A total volume of 24,787 shares were traded at the close of the day’s session.
In the last one week, shares of Unity Biotechnology Inc have slipped by -4.2%.
Unity Biotechnology Inc's Key Ratios
Unity Biotechnology Inc has a market cap of $38.26 million, indicating a price to book ratio of 0.5203 and a price to sales ratio of 7.8878.
In the last 12-months Unity Biotechnology Inc’s revenue was $0 with a gross profit of $-35223000 and an EBITDA of $-47076000. The EBITDA ratio measures Unity Biotechnology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Unity Biotechnology Inc’s operating margin was 0% while its return on assets stood at -30.63% with a return of equity of -114.05%.
In Q2, Unity Biotechnology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Unity Biotechnology Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Unity Biotechnology Inc’s profitability.
Unity Biotechnology Inc stock is trading at a EV to sales ratio of 3.8736 and a EV to EBITDA ratio of 0.2022. Its price to sales ratio in the trailing 12-months stood at 7.8878.
Unity Biotechnology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $101.01 million
- Total Liabilities
- $22.22 million
- Operating Cash Flow
- $9.85 million
- Capital Expenditure
- Dividend Payout Ratio
Unity Biotechnology Inc ended 2023 with $101.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $101.01 million while shareholder equity stood at $49.41 million.
Unity Biotechnology Inc ended 2023 with $0 in deferred long-term liabilities, $22.22 million in other current liabilities, 1000.00 in common stock, $-483021000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.12 million and cash and short-term investments were $69.09 million. The company’s total short-term debt was $13,704,000 while long-term debt stood at $4.08 million.
Unity Biotechnology Inc’s total current assets stands at $72.97 million while long-term investments were $1.90 million and short-term investments were $49.97 million. Its net receivables were $1.74 million compared to accounts payable of $1.45 million and inventory worth $1.76 million.
In 2023, Unity Biotechnology Inc's operating cash flow was $9.85 million while its capital expenditure stood at $0.
Comparatively, Unity Biotechnology Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Unity Biotechnology Inc stock is currently trading at $2.51 per share. It touched a 52-week high of $5.72 and a 52-week low of $5.72. Analysts tracking the stock have a 12-month average target price of $7.67.
Its 50-day moving average was $2.7 and 200-day moving average was $3.09 The short ratio stood at 7.66 indicating a short percent outstanding of 0%.
Around 143.1% of the company’s stock are held by insiders while 2913.3% are held by institutions.
Frequently Asked Questions About Unity Biotechnology Inc
Similar Industry Stocks (Biotechnology)
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.